Asian Tech Press (Nov 5) -- Chinese pharmaceutical company Sinovac Biotech Ltd (SVA: NASDAQ GS) said in a release Friday that its COVID-19 vaccine has a good safety profile in healthy people aged 3-17 years in various ethnic groups.

A Phase III multicenter, case-driven, randomized, double-blind, placebo-controlled clinical study of Coronavac, the COVID-19 vaccine developed by Sinovac, is underway in a healthy population aged 6 months to 17 years in South Africa, Chile, Malaysia and the Philippines.

As of October 29, 2021, a total of 2,140 subjects have been enrolled, including 684 subjects in the safety subgroup.

Analysis of safety data for this subgroup in a blinded setting showed that Coronavac has a favorable safety profile in healthy populations aged 3-17 years in different ethnic groups.

The Chinese vaccine company said that since September this year, several countries, including Chile, Ecuador, El Salvador, Colombia, Cambodia and Indonesia, have approved the use of Coronavac for the vaccination of minors aged 3-17 years.

In China, by the end of October, more than 110 million doses of Sinovac COVID-19 vaccine had been administered to minors under the age of 18.